NCT06001684View on ClinicalTrials.gov

Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

December 30, 2024

Conditions
Solid Tumors
Interventions
BIOLOGICAL

IBR854 Cell Injection

The minimum initial dose is 3.0×10\^9 cells and then escalate to 5.0×10\^9 cells and 7.0×10\^9 cells. Every 21 days is one cycle, and intravenous infusion is performed on day 1 and day 8 of each cycle.

Trial Locations (1)

100021

RECRUITING

Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors
lead

Imbioray (Hangzhou) Biomedicine Co., Ltd.

INDUSTRY